Tag: Biosimilar
Lupin receives European Commission approval for Biosimilar Ranibizumab
Lupin’s biosimilar ranibizumab will be commercialized by Sandoz across the European Union (excluding Germany)
Zydus launches biosimilar Aflibercept 2 mg ANYRA™ for advancing ophthalmic care
ANYRA™ is India’s first indigenously developed Aflibercept 2 mg biosimilar
Samsung Bioepis flags shifting PBM models and deepening price erosion in...
Q1 2026 Biosimilar Market Report tracks approvals, launches, pricing trends, and the potential impact of evolving PBM rebate frameworks on biosimilar uptake
Zydus launches Tishtha, the world’s first biosimilar of Nivolumab, in India...
The immunotherapy reduces treatment burden by making it accessible at approximately 1/4th cost of the reference drug
Zydus, Formycon forge exclusive deal to license & supply Keytruda biosimilar...
The BLA application is expected to be submitted to the USFDA in the near future and is aimed at making immunotherapy affordable and accessible to patients in need
Lupin and Valorum enter into an exclusive licensing agreement for ‘Biosimilar...
The company will be responsible for manufacturing and supply of the product and will receive an upfront license fee and a royalty payment on net sales
Lupin receives approval from U.S. FDA for biosimilar Armlupeg™ (Pegfilgrastim-unne)
The product will be manufactured at Lupin’s Biotech facility in Pune, which was inspected by the U.S. FDA prior to approval.
OneSource and Xbrane Biopharma enter into strategic biosimilars manufacturing partnership for...
The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the US launch
India Biotech Outlook 2025: The India Advantage at BIO Boston 2025
BioVoice News and the International Contract Pharma Association (ICPA) have collaborated to present an exclusive publication that will highlight India’s leadership in biotech and provide a powerful platform for companies to maximize their presence
Lupin receives Health Canada approval for biosimilar Pegfilgrastim
This product will be marketed under the brand name Armlupeg® and manufactured at Lupin’s Biotech facility at Pune, India